4.5 Article

COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest

期刊

BRAIN RESEARCH
卷 1519, 期 -, 页码 71-77

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.brainres.2013.04.029

关键词

Prostaglandin; Cyclopentenone; Hypoxic-ischemia; Cardiac arrest; Cyclooxygenase

资金

  1. National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1 RR024153-05]
  2. NIH Roadmap for Medical Research
  3. [R21HD058846]
  4. [R01NS37459]

向作者/读者索取更多资源

Background: Cyclopentenone prostaglandins have been identified as potential neurotoxic agents in the setting of hypoxia-ischemia. Cyclooxygenase-2 (COX-2), the upstream enzyme responsible for prostaglandin production is upregulated following hypoxic-ischemic brain injury. However, the temporal production and concentration of cyclopentenone prostaglandins has not been described following global brain ischemia. Methods Global brain ischemia was induced in rats by asphyxial cardiac arrest (ACA) followed by resuscitation. Rats were sacrificed between 24 h and 7 days following resuscitation and their brains removed. Western blot, immunohistochemistry, and mass spectroscopy were performed. A cohort of rats was pretreated with the COX-2 inhibitor SC58125. Results COX-2 is induced in hippocampus at 24 h following ACA. Multiple prostaglandins, including cyclopentenone prostaglandin species, are increased in hippocampus as 24 h following ACA. Prostaglandin and cyclopentenone prostaglandin concentrations are returned to baseline at 3 and 7 days post-ischemia. The COX-2 inhibitor SC58125 completely abrogates the post-ischemic increase in prostaglandins and cyclopentenone prostaglandins. Conclusions Prostaglandins, including cyclopentenone prostaglandins, are increased in ischemic brain, peak at 24 h and can be attenuated by the COX-2 inhibitor SC58125. These data establish the presence of potentially neurotoxic cyclopentenone prostaglandins in post-ischemic brains, thus identifying a target and therapeutic window for neuroprotective therapies. (C) 2013 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据